WO2015138702A1 - Improved measurement of body fluid volumes - Google Patents

Improved measurement of body fluid volumes Download PDF

Info

Publication number
WO2015138702A1
WO2015138702A1 PCT/US2015/020140 US2015020140W WO2015138702A1 WO 2015138702 A1 WO2015138702 A1 WO 2015138702A1 US 2015020140 W US2015020140 W US 2015020140W WO 2015138702 A1 WO2015138702 A1 WO 2015138702A1
Authority
WO
WIPO (PCT)
Prior art keywords
molecule
animal
vascular system
tvpv
ecfv
Prior art date
Application number
PCT/US2015/020140
Other languages
French (fr)
Inventor
Bruce A. Molitoris
Exing Wang
Ruben M. Sandoval
Original Assignee
Pharmacophotonics, Inc. D/B/A Fast Biomedical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/208,828 external-priority patent/US20140193343A1/en
Application filed by Pharmacophotonics, Inc. D/B/A Fast Biomedical filed Critical Pharmacophotonics, Inc. D/B/A Fast Biomedical
Priority to US15/125,412 priority Critical patent/US20170173188A1/en
Priority to EP15761804.2A priority patent/EP3117211A4/en
Publication of WO2015138702A1 publication Critical patent/WO2015138702A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14507—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood
    • A61B5/1451—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue specially adapted for measuring characteristics of body fluids other than blood for interstitial fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/20—Measuring for diagnostic purposes; Identification of persons for measuring urological functions restricted to the evaluation of the urinary system
    • A61B5/201—Assessing renal or kidney functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4869—Determining body composition
    • A61B5/4875—Hydration status, fluid retention of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4869—Determining body composition
    • A61B5/4881—Determining interstitial fluid distribution or content within body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal

Definitions

  • the present invention is related generally to measurement of body fluid volumes in an animal subject.
  • the body fluid volumes of interest include extracellular fluid volume (ECFV), total vascular plasma volume (TVPV) and interstitial fluid volume (WV), with TVPV being the preferred indicator,
  • ECFV extracellular fluid volume
  • TVPV total vascular plasma volume
  • WV interstitial fluid volume
  • the methods are especially beneficial for subjects suffering from renal failure, and particularly those undergoing renal dialysis.
  • Body fluid volume status is a critical metric in the management of many chronic and acute medical conditions. Volume status is a key determinant in drag dosing, pharmacokinetics, blood pressure and organ perfusion, Volume status and volume management are most critical in indications or conditions such as, but are not limited to, end stage renal disease (ESRD), ' hypertension, congestive heart failure, septic shock and hypovolemia, acute kidney injury and chronic kidney disease (CKD), hypertension, syncope, acute blood loss, pre-surgieal screening, orthostatic hypotension and anemia in cancer or HIV.
  • ESRD end stage renal disease
  • CKD acute kidney injury and chronic kidney disease
  • hypertension syncope
  • acute blood loss pre-surgieal screening
  • orthostatic hypotension and anemia in cancer or HIV evaluating total vascular plasma volume and interstitial fluid volume in dialysis patients has very important implications especially with regard to removal of volume while on dialysis. This is clinically very important for control of blood pressure and clinical outcomes in patients with end stage renal disease (ESRD)
  • a commonly used technique for estimating the TVPV is based on the concept of the indicator dilution technique in which an indicator molecule is mixed and distributed into an unknown volume. An identical amount of the indicator molecule is placed into a known volume, The unknown volume can be measured by comparing the concentration of the indicator between the known and unknown volume.
  • a common indicator molecule that is being used is albumin labeled with various dyes, such as radioactive iodine or I ) or the fluorescent dye indocyanine green (ICG).
  • I radioactive iodine
  • ICG indocyanine green
  • ICG-labeled albumin was measured by near infra-red absorption of the molecule. Functionally, there is little difference between the use of ICG when compared to I s ji , as both quickly bind to albumin in the bloodstream.
  • the main distinguishing characteristics are the relatively short half life of ICG as compared to I LU and the beneficial safety profile of ICG.
  • ICG is already approved for human use by the United States Food And Drug Administration (FDA).
  • FDA United States Food And Drug Administration
  • the short half life of ICG all ws for multiple tests to be conducted with rapid succession.
  • utility of the ICG method has been limited by many of the same factors as the iodine- based testing. Though the time period for collecting samples of ICG is much shorter than the radioactive test, it becomes all the more important to make certain that sampling is conducted at precise time intervals. Therefore, it is a very labor intensive method.
  • albumin in the dilution technique to measure plasma volume, Is thai albumin also "leaks" and distributes to the interstitial fluid. Under physiologic conditions, albumin "leaks” into the interstitial space at a rate of about 5% per hour. This rate increases to 15% per hour in patients with septic shock (see U.S. Pat. No, 6,355,624). Thus, albumin does not measure the true TVPV or plasma volume, but rather it measures the combination of the TVPV and the IFV.
  • the present invention is provided to solve the problems discussed above and other problems, and to provide advantages and aspects not provided by prior techniques. A full discussion of the features and advantages of the present invention is deferred to the following detailed description.
  • One aspect of the present invention is directed to methods for measuring extraeeullar fluid volume (ECFV) in an animal with renal failure.
  • the method comprises: (a) administering a sufficient amount (Aj) of a first molecule to the vascular system of the animal wherein the first molecule is non-metabolized and permeable to vessel wails of the vascular system; (b) allowing the first molecule to reach a first equilibrium steady state concentration (Q) in the vascular system of the animal; (c) measuring the Cj in the vascular system of the animal; and (d) calculating the ECFV using the equation;
  • the first molecule may be administered by intravenous injection of an mjectate containing the first molecule.
  • the intravenous injection can he bolus or continuous infusion.
  • the first molecule may be administered by inhalation.
  • the first molecule has a molecular size of from about I kDa to about 20 kDa.
  • the first molecule is dextran.
  • the first molecule is labeled with a first fluorescent dye and the first molecul is detected and quantified by the fluorescence intensity of the molecule.
  • the first, molecule can be detected using an antibody
  • the first fluorescent dye can be selected from, but not limited to, xanthene dye, CAL FLOUR®, ALEXA FLUOR®, OREGON GREEN®, carbocyamne, fluorescein, fluorescein isothiocyanate (FITC), carboxy ffuoreseeein, eyanine, rhodamine, tetramethylrhodamine (Tamra), tetramethyl rhodamine othiocyanate (TRITC), X rhodamine isothiocyanate (XRITC), TEXAS RED ⁇ , and indocyanine green (ICG).
  • xanthene dye CAL FLOUR®, ALEXA FLUOR®
  • OREGON GREEN® carbocyamne
  • fluorescein fluorescein isothiocyanate
  • FITC fluorescein isothiocyanate
  • carboxy ffuoreseeein eyanine
  • Measurement of the concentration of the first molecular dye in the vascular- system can be performed in vitro or in vivo.
  • a sample of blood can be drawn from the animal after the first molecule has reached a steady state equilibrium concentration in the vascular- system of the animal,
  • a plasma or serum supernatant is prepared from the blood sample by a method such as, but not limited to, centrifugation or filtration.
  • the fluorescence intensity of the first molecule can be measured in the supernatant, in another embodiment, an ELISA assay can also be used to determine the level of the fluorescent molecule in the plasma or serum, in the in vivo method, the fluorescence intensity of the first molecule is measured directly in vivo within the vascular system of the animal without having to remove a blood sample from the animal
  • a preferred method for in vivo measurement of the first molecule is to use a first molecule labeled with a first fluorescent dye.
  • Another aspect of the invention is directed to methods for determining total vascular plasma volume (TVPV) in an animal comprising: (a) administering a sufficient amount (A 2 ) of a second molecule to the vascular system of the animal, wherein the second molecule is non-metabolized and impermeable to vessel walls of the vascular system; (b) allowing the second molecule to reach a second equilibrium steady state concentration in the plasma within the vascular- system of the animal; (c) measuring the second equilibrium steady state concentration ( € 2 ) of the second molecule; and calculating the TVPV using the equation: TVPV-A 2 /C 2 .
  • the second molecul has a molecular size of from about 70 kDa to about 500 kDa, in another embodiment, the second molecule is a dexlran. In yet another embodiment, the second molecule is labeled with a second fluorescent dye and the second molecule can be detected by the emission fluorescence intensity of the molecule, In a still further embodiment, the first molecule can be detected using an antibody (monoclonal or polyclonal) to the fluorescent molecule in an ELISA assay.
  • the first fluorescent dye can be selected from, but not limited to, xanthene dye, CAL FLOUR®, ALEXA FLUOR®, OREGON GREEN®, carbocyanine, fluorescein, fluorescein isothiocyanate (FITC), earhoxy fmoreseeein, cyanine, rhodamine, tetrameihylrhodamine (Tamra), tetramethyl rhodamine isothiocyanate (TRITC), X rhodarrdne isothiocyanate (XRITC). TEXAS RED®, and indocyanine green (ICG),
  • Measurement of the concentration of the second molecule in the vascular system can be performed in vitro or in vivo,
  • a sample of blood is drawn from the animal after the second molecule has reached a steady state equilibrium concentration in the vascular system of the animal.
  • a plasma or serum supernatant is prepared from die blood sample by a method such as, but not limited to, ceutrifugation or filtration.
  • the concentration of the second molecule is measured in the plasma or semm supernatant.
  • an ELISA assay can also be used to determine the level of the fluorescent molecule in the plasma or serum.
  • the second molecule is measured directly in vivo within the vascular system of the animal without having to remove a blood sample from the animal.
  • a preferred method for in vivo measurement of the second molecule is to use a second molecule labeled with a second fluorescent dye,
  • ECFV extracellular fluid volume
  • TVPV total vascular plasma volume
  • An apparatus for determining the ECVF and TVPV using these methods may comprise; (a) means for providing the injectate to the vascular system of the animal; (b) means for measuring C ⁇ and C3 ⁇ 4 in vivo in the vascular system of the animal; (c) means for calculating ECFV and TVPV; and (d) means for displaying the calculated values of ECFV and TVPV.
  • the apparatus may further comprise means for calculating iFV and displaying the calculated value of iFV,
  • the apparatus may be a stand alone unit or incorporated into a hemodialysis device.
  • FIG, 1 shows a decay curve (o) of the fluorescence from the larger fluorescent marker 150-kDa FiTC-dextran which was administered to a bilaterally anephric rat as described in Example 1, Also shown is the smoothed fluorescence curve (— ) of the fluorescence from the 150-kDa FiTC-dextran as well as a decay curve of the ratio of the fluorescence from the 3-kDa Texas ed-dextran to that of the 150-kDa FFfC dextran (— .cndot.---).
  • the present invention is related generally to measurement of body fluid volumes in an animal subject.
  • the body fluid volumes of proteins include extracellular fluid volume (ECFV), total vascular plasma volume (TVPV) and i terstitial fluid volume (WV).
  • ECFV extracellular fluid volume
  • TVPV total vascular plasma volume
  • WV i terstitial fluid volume
  • the methods are especially beneficial for subjects suffering from renal failure and particularly those undergoing renal dialysis.
  • the animal subject may be a mammalian subject, and the mammalian subject may be a human,
  • the renal failure may be acute or chronic. Acute renal failure may be due to acute renal injury, and chronic renal failure may be due to late stage renal disease (ESRD). Renal dialysis can be hemodialysis or peritoneal dialysis if the abdominal cavity is dry.
  • the renal failure may also be temporary or permanent.
  • ECFV can be measured by administering a first molecule which is non- metabolized and permeable to vessel wails of the vascular system wherein the first molecule is distributed within the total vascular spaces as well as the interstitial spaces.
  • TVPV can be measured by administering a second molecule which is non-metabolized and impermeable to vessel walls of the vascular system wherein the second molecule is distributed within only the vascular spaces.
  • TVPV total vascular plasma volume
  • WV interstitial fluid volume
  • IFV a good indicator for capillary leakage
  • ECFV extracellular fluid volume
  • Total blood volume (TBV) can be estimated from the TVPV by adding TVPV and the volume contributed by the blood cells, which can be determined from the Hematocrit (Hc ) or from the Packed Cell Volume (PCV),
  • One aspect of the present invention is directed to methods for measuring extraceullar fluid volume (ECFV) in an animal with renal failure.
  • the method comprises: (a) administering a sufficient amount (Ai) of a first molecule to the vascular system of the animal wherein the first molecule is non-metabolized and permeable to vessel walls of the vascular system; (b) allowing the first molecule to reach a first equilibrium steady state concentration (Cj) in the vascular system of the animal; (c) measuring the Ci in the vascular system of the animal; and (d) calculating the ECFV using the. equation:
  • Another aspect of the present invention is directed to methods for determining total vascular plasma volume (TVPV) in an animal comprising: (a) administering a sufficient amount (A 2 ) of a second molecule to the vascular system of the animal, wherein the second molecule is non-metabolized and impermeable to vessel wails of the vascular system; (b) allowing the second molecule to reach a second equilibrium steady state concentration in th plasma within the vascular system of the animal; (c) measuring the second equilibrium steady state concentration ( € ) of the second molecule; and calculating the TVPV using the equation; TVPV ⁇ A 2 /C 2 ,
  • interstitial fluid volume can be calculated using the equation:
  • the molecule is above the detection limit using an appropriate analytical technique after the molecule has reached equilibrium following distribution.
  • the appropriate analytical method depends on the properties and characteristics of the molecule.
  • the time for the first molecule or the second molecule to reach its respectively steady state equilibrium concentration depends on the molecule and the animal species. Such time for reaching equilibrium can easily be determined by dosing the animal with the molecule and monitoring the molecule in the vascular system of the animal over time. Initially, the concentration of the molecule rises in the vascular system, which represents a mixing phase of the molecule in the vascular system. Eventually, the concentration of the molecule reaches an equilibrium steady state in the vascular system when the concentration plateaus. The beginning of the plateau of the concentration of the molecule marks the end of the mixing phase, An example of such a method is described in
  • Example 1 This equilibrium time is relatively constant for a specific molecule and a specific animal species so that once such time is determined for the molecule and the animal species, the value can be used for the same molecule and the same animal species without having to determine the value again.
  • the equilibrium time In human beings, the equilibrium time, is about 10 to 15 minutes for most molecules. However, in certain disease states, such as congestive heart failure, it may take longer time to reach equilibrium.
  • the first molecule or the second molecule may be administered by a suitable method such as intravenous injection of an injectate containing the first molecule and/or the second molecule,
  • the intravenous injection can be bolus or continuous infusion over a period of time.
  • non-metabolized is that the molecule is not significantly metabolized by the animal during the time in which the measurements are performed
  • permeable to vessel walls refers to that the molecule can cross the vessel walls. This movement of the molecule can be a passive method without requiring energy, e.g. diffusion, or an active method requiring energy, e.g. active transport.
  • impermeable to vessel walls refers to that the molecule cannot cross the vessel walls either through a passive process or an active process.
  • An EL1SA assay uses a solid-phase enzyme immunoassay (FJA) to detect the presence of the fluorescent dye attached to the dextran.
  • FJA solid-phase enzyme immunoassay
  • the fluorescent dye is affixed to a surface, and an antibody (monoclonal or polyclonal) is applied to the surface to bind with the dye.
  • the antibody is linked to an enzyme, and in the final step, a substance containing the enzyme's substrate is added. The subsequent reaction produces a detectable signal, most commonly a color change in the substrate, ELISA assays are generally well known in the art.
  • the first molecule has a molecular size of from about 1 kDa to about 20 kDa
  • the second molecule has a molecule size of from about 70 kDa to about 500 kDa.
  • the first or the second molecule are dextrans.
  • the first molecule or the second molecule is a fluorescent molecule
  • the first molecule is a dextran labeled with a first fluorescent dye having a first excitation wavelength and a first emission wavelength.
  • the second molecule is a dextran labeled with a second fluorescent dye having a second excitation wavelength and. a second emission wavelength
  • the first or second fluorescent dye can be selected from, but not limited to, xanthene dye, CAL FLOUR®, ALEXA FLUOR ⁇ , OREGON
  • GREEN® carbocyanine, fluorescein, fluorescein isothiocyanate (FITC), carboxy fluoresecein, cyanine, rhodamine, tetranietnylrhodamine (Tamra), tetramethy! rhodamine isothiocyanate (TR1TC), X rhodamine isothiocyanate (XRITC), TEXAS RED® and indocyanine green (ICG).
  • Measurement of the concentration of the first molecule or the second molecule in the vascular system can be performed in vitro or in vivo.
  • a sample of blood is drawn from the animal after the first molecule or the second molecule has reached a steady state equilibrium concentration in the vascular system of the animal.
  • a plasma or semm supernatant of the blood is prepared from the blood sample by a method which removes the blood cells from the blood, such as, but not limited to, centrifugation or filtration, These separation methods are well known to those skilled in the art and are routinely practiced in the laboratory.
  • the supernatant represents th piasrna of the blood.
  • the concentration of the first molecule or the second molecule can be measured in the supernatant by an appropriate detection method such as absorption spectroscopy, fluorescence, or by using an ELISA immunoassay as described in mor detail in the Examples.
  • the first or the second molecule is measured directly in vivo within the vascular system of the animal wi thout having to remove a blood sample from the animal.
  • a preferred method for in vivo measurement of a molecule is to use a molecule labeled with a fluorescent dye.
  • An example of an in vivo measurement of a fluorescent molecule in the vascular system of the animal has been disclosed in a pending U.S. Pat. No. 12/425,827 which is incorporated herein by referenc and made a part of the present application. The method is applicable to measuring one or more fluorescent molecules simultaneously in vivo.
  • a further aspect of the invention is directed to methods for simultaneously measuring extracellular fluid volume (ECFV) and total vascular volume (TVPV) in an animal with renal failure comprising: (a) providing an injeetate containing a known amount Ai of a first molecule and a known amount A 2 of a second molecule, wherein the first molecule is non-metabolized and permeable to vessel walls of the vascular system of the animal and the second molecule is non-metabolized and impermeable to vessel walls of the vascular system of the animal; (b) administering the injeetate into the vascular system of the animal; (c) allowing the first molecule to reach a first equilibrium steady state concentration Cs and the second molecule to reach a second equilibrium steady state concentration C 2 ; (d) measuring d and C 2 in the vascular system of the animal; and (e) calculating ECFV using the equation and TVPV using the equation
  • Measurement of the concentration of the first molecule and the second molecule in the vascular system can be performed in vitro or in vivo.
  • a sample of blood is drawn from the animal after the first molecule and the second molecule have each reached a steady state equilibrium concentration in the vascular system of the animal, A plasma or serum supernatant is prepared from the blood sample by a method such as, hut not limited to, centrifug tion or filtration.
  • the concentration of the first molecule and the second molecule is measured in the supernatant.
  • the first molecule and the second molecule are measured directly in vivo within the vascular system of the animal without having to remove a blood sample from the animal.
  • a preferred method for in vivo measurement of the first molecule and the second molecule is to use a first molecule labeled with a first fluorescent dye and a second molecule labeled with second fluorescent dye,
  • An apparatus for determining the ECFV and TVPV using these methods may comprise: (a) means for providing the injectate to the vascular system of the animal; (b) means for measuring Ci and C 2 in vivo in the vascular system of the animal; fe) means for calculating ECFV and TVPV; and (d) means for displaying the calculated values of ECFV and TVPV.
  • the apparatus may further comprise means for calculating IFV and displaying the calculated value of IFV.
  • the apparatus may be a stand alone unit or incorporated into a hemodialysis device.
  • compositions of the invention can be typically used in a clinic or hospital where the treatment of renal disease and renal failure are indicated.
  • the example shown here was a test conducted on a bilaterally anephric rat, which was infused with a mixture of 3 kDa TEXAS RED®-dextran and 150 kDa FiTC-dextran.
  • the dynamic plasma fluorescence intensity was obtained by in vivo two-photon liver imaging of vascular plasma. Only the vascular plasma containing regions in each image were included for calculation.
  • the decay curve of the fluorescence intensity of the 150- kDa FiTC- dextran as well as the decay curve of the ratio of the fluorescence intensity of the TEXAS RED ⁇ -dextran to that of the FiTC-dextran after the infusion is shown in FIG. L Using the ratio rather than the 3 kDa TEXAS RED® ⁇ dextran or the 150 kDa FiTC-dextran signal directly helped reduce the signal fluctuation caused by focus movement during imaging since the same fluctuation showed up in both channels.
  • Example 2 Anticipated Minimally Invasive Method for Measuring Fluid Volumes in a
  • a minimally invasive method for measuring TVPV, ECFV and TV in a patient with renal failure uses a small dextran (molecule size of about 1 kDa to about 20 kDa) labeled with a first fluorescent dye to distribute to the vascular and interstitial spaces and a large dextran (molecule size of about 70 kDa to about 500 kDa) labeled with a second fluorescent dye to distribute only to the vascular space of the animal.
  • the molecules can be simultaneously detected in vivo using a dual channel fluorescence detection device and a proprietary fiber optic catheter.
  • the fluorescence device and the fiber optic catheter have both been disclosed in a pending U.S. Patent Application Ser. No, 12/425,827, the disclosure of which is hereby incorporated by reference as if fully set forth herein and, more specifically, for this specific subject matter disclosed at Paragraphs [0077] to
  • FIGS. 1 and 91-14 for the detector, and Paragraphs [0108] to [0112] and FIGS, 1, 16, and 17 for the fiber optic catheter,
  • the method comprises: (1 ) inserting the proprietary fiber optic catheter into a peripheral vein in the patient's upper extremity; (2) connecting the fiber optic catheter to the fluorescence device; (3) attaching a syringe containing 5 to 10 ml of an injectate containing the small and large fluorescent dextrans to the catheter; (4) injecting 1 ml of the injectate into the calibration chamber of the catheter, and backfilling with patient's blood; (5) calibrating the fluorescence detection device; (6) advancing the fiber optic line through the catheter and into the catheter; (7) allowing enough time (approximately 10 to 15 minutes) for the molecules to equilibrate in the patient; (S) detecting the fluorescence intensities of the small and large dextrans with the fluorescence device; (9) calculating the fluid volumes using a pre-programmed algorithm; and (10) displaying the values of the fluid volumes on a screen.
  • Determination of plasma volume is accomplished using a 150 kDa dextran conjugated to a 2-Sulf ydroRhodamine (2SHR) fluorescent dye, A bolus injection or alternatively a rapid infusion of the molecule is given to the subject.
  • a blood sample is taken approximately 10 to 15 minutes after the molecule enters the subjects blood stream. The sample is analyzed to determine the concentration of the molecule in the blood plasma.
  • PV plasma volume
  • the ELIS A coiorimeirie assay is incorporated into a module that allows determination of the plasma volume at the patient's bedside.
  • a pair of ELiSA assays on one module allows for both PV and GFR (glomerular filtration rate) determination, the difference being that for the GFR detennination, more than one blood sample is drawn and measured.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention is related generally to measurement of body fluid volumes in an animal subject. The body fluid volumes of interest include extracellular fluid volume (ECFV), total vascular plasma volume (TVPV) and interstitial fluid volume (IFV). The methods are especially beneficial for subjects suffering from renal failure and particularly those undergoing renal dialysis. ECFV can be measured by administering a first molecule which is non-metabolized and permeable to vessel walls of the vascular system wherein the first molecule is distributed within the total vascular space as well as the interstitial space. TVPV can be measured by administering a second molecule which is non-metabolized and impermeable to vessel walls of the vascular system wherein the second molecule is distributed within only the vascular space. IFV can then be calculated using the equation IFV=ECFV-TVPV.

Description

IMPROVED MEASUREMENT OF BODY FLUID VOLUMES
CROSS-REFERENCE TO RELATED APPLICATIONS
The present invention is a continuation-in-part of U.S. Patent Application No. 13/318,097, filed April 18, 2012, which is a 371 filing claiming priority to
PCT/US201Q/032997, filed April 29, 2010, and claims the benefit of U.S. Provisional Patent Application No, 61/174,100 filed Apr. 30, 2009, and the contents of which are incorporated herein by reference in their entirety.
BACKGROUND OF THE INVENTION
The present invention is related generally to measurement of body fluid volumes in an animal subject. The body fluid volumes of interest include extracellular fluid volume (ECFV), total vascular plasma volume (TVPV) and interstitial fluid volume (WV), with TVPV being the preferred indicator, The methods are especially beneficial for subjects suffering from renal failure, and particularly those undergoing renal dialysis.
Body fluid volume status is a critical metric in the management of many chronic and acute medical conditions. Volume status is a key determinant in drag dosing, pharmacokinetics, blood pressure and organ perfusion, Volume status and volume management are most critical in indications or conditions such as, but are not limited to, end stage renal disease (ESRD), 'hypertension, congestive heart failure, septic shock and hypovolemia, acute kidney injury and chronic kidney disease (CKD), hypertension, syncope, acute blood loss, pre-surgieal screening, orthostatic hypotension and anemia in cancer or HIV. In addition, evaluating total vascular plasma volume and interstitial fluid volume in dialysis patients has very important implications especially with regard to removal of volume while on dialysis. This is clinically very important for control of blood pressure and clinical outcomes in patients with end stage renal disease (ESRD) who all require chronic form of dialysis or renal replacement therapy (RRT) for volume removal. The importance of volume status and volume management in dialysis patients
I has been discussed by Agarwal R, et ai. ("Diagnostic Utility of Blood Volume
Monitoring in Hemodialysis Patients" Am J of Kidney Diseases (2008) 51: 242-254), Rodriguez H. J„ et a3, ("Assessment of Dry Weight by Monitoring Changes in Blood Volume During Hemodialysis using Crit-Line" Kidney International (2005) 68, 854-861 ), Kraemer M. et al. ("Detection Limit of Methods to Assess Fluid Status Changes in Dialysis Patients" Kidney international (2006) 69: 16094620) and Dasselaar J. J, et ai. ("Measuiment of Relative Blood Volume Changes During Haemodialysis: Merits and Limitations" Nephrol Dial Transplant (2005) 20: 2043-2049).
A commonly used technique for estimating the TVPV is based on the concept of the indicator dilution technique in which an indicator molecule is mixed and distributed into an unknown volume. An identical amount of the indicator molecule is placed into a known volume, The unknown volume can be measured by comparing the concentration of the indicator between the known and unknown volume. A common indicator molecule that is being used is albumin labeled with various dyes, such as radioactive iodine or I ) or the fluorescent dye indocyanine green (ICG). For example, Daxor Corporation (New York, N. Y.) has developed a device for measuring blood volume using albumin labeled with I131 as the tracer indicator. Use of ICG-labeled albumin as the tracer indicator has been disclosed by Mi ra, S. et ai. ("Serial Determinations of Absolute Plasma Volume with Indocyanine Green During Hemodialysis," J Am Soc of
Nephrology, (2003) 14(9): 2345-51). In this method, ICG-labeled albumin was measured by near infra-red absorption of the molecule. Functionally, there is little difference between the use of ICG when compared to Is ji, as both quickly bind to albumin in the bloodstream. The main distinguishing characteristics are the relatively short half life of ICG as compared to ILU and the beneficial safety profile of ICG. ICG is already approved for human use by the United States Food And Drug Administration (FDA). The short half life of ICG all ws for multiple tests to be conducted with rapid succession. However, utility of the ICG method has been limited by many of the same factors as the iodine- based testing. Though the time period for collecting samples of ICG is much shorter than the radioactive test, it becomes all the more important to make certain that sampling is conducted at precise time intervals. Therefore, it is a very labor intensive method.
Another drawback in the use of labeled albumin, in the dilution technique to measure plasma volume, Is thai albumin also "leaks" and distributes to the interstitial fluid. Under physiologic conditions, albumin "leaks" into the interstitial space at a rate of about 5% per hour. This rate increases to 15% per hour in patients with septic shock (see U.S. Pat. No, 6,355,624). Thus, albumin does not measure the true TVPV or plasma volume, but rather it measures the combination of the TVPV and the IFV.
Another method that is used to measure body fluid volumes is the use of bioimpedence spectroscopy. This approach has been discussed by Zhu et al. ("Segment- Specific Resistivity Improves Body Fluid Volume Estimates from Bioimpedence Spectroscopy in Hemodialysis Patients" J Appl Physio (2006) 100: 717-724), De Lorenzo A, et al. ("Predicting Body Cell Mass With Bioimpedanee by Using Theoretical Methods: a Technological Review" J Appl Physiology (1997) 82: 1542-1558) and Kuhlmann, M, K. et al ("Bioimpedence, Dry Weight and Blood Pressure Control: New Methods and Consequences" Current Opinion in Nephrology and Hypertension (2005) 14: 543-549). However, this technique is too difficult and impractical to perform.
Therefore, there is a clinical need to develop a minimally invasive method to accurately and inexpensive quantify these body fluid volumes. The present invention is provided to solve the problems discussed above and other problems, and to provide advantages and aspects not provided by prior techniques. A full discussion of the features and advantages of the present invention is deferred to the following detailed description.
SUMMARY OF THE INVENTION
One aspect of the present invention is directed to methods for measuring extraeeullar fluid volume (ECFV) in an animal with renal failure. The method comprises: (a) administering a sufficient amount (Aj) of a first molecule to the vascular system of the animal wherein the first molecule is non-metabolized and permeable to vessel wails of the vascular system; (b) allowing the first molecule to reach a first equilibrium steady state concentration (Q) in the vascular system of the animal; (c) measuring the Cj in the vascular system of the animal; and (d) calculating the ECFV using the equation;
ECFV=A{/Ci. The first molecule may be administered by intravenous injection of an mjectate containing the first molecule. The intravenous injection can he bolus or continuous infusion. Alternatively, the first molecule may be administered by inhalation.
In an embodiment, the first molecule has a molecular size of from about I kDa to about 20 kDa. In another embodiment, the first molecule is dextran. In yet another embodiment, the first molecule is labeled with a first fluorescent dye and the first molecul is detected and quantified by the fluorescence intensity of the molecule. In a still further embodiment, the first, molecule can be detected using an antibody
(monoclonal or polyclonal) to the fluorescent molecule in an assay.
The first fluorescent dye can be selected from, but not limited to, xanthene dye, CAL FLOUR®, ALEXA FLUOR®, OREGON GREEN®, carbocyamne, fluorescein, fluorescein isothiocyanate (FITC), carboxy ffuoreseeein, eyanine, rhodamine, tetramethylrhodamine (Tamra), tetramethyl rhodamine othiocyanate (TRITC), X rhodamine isothiocyanate (XRITC), TEXAS RED©, and indocyanine green (ICG).
Measurement of the concentration of the first molecular dye in the vascular- system can be performed in vitro or in vivo. In the in vitro method, a sample of blood can be drawn from the animal after the first molecule has reached a steady state equilibrium concentration in the vascular- system of the animal, A plasma or serum supernatant is prepared from the blood sample by a method such as, but not limited to, centrifugation or filtration. In one embodiment, the fluorescence intensity of the first molecule can be measured in the supernatant, in another embodiment, an ELISA assay can also be used to determine the level of the fluorescent molecule in the plasma or serum, in the in vivo method, the fluorescence intensity of the first molecule is measured directly in vivo within the vascular system of the animal without having to remove a blood sample from the animal A preferred method for in vivo measurement of the first molecule is to use a first molecule labeled with a first fluorescent dye.
Another aspect of the invention is directed to methods for determining total vascular plasma volume (TVPV) in an animal comprising: (a) administering a sufficient amount (A2) of a second molecule to the vascular system of the animal, wherein the second molecule is non-metabolized and impermeable to vessel walls of the vascular system; (b) allowing the second molecule to reach a second equilibrium steady state concentration in the plasma within the vascular- system of the animal; (c) measuring the second equilibrium steady state concentration (€2) of the second molecule; and calculating the TVPV using the equation: TVPV-A2/C2.
In an embodiment, the second molecul has a molecular size of from about 70 kDa to about 500 kDa, in another embodiment, the second molecule is a dexlran. In yet another embodiment, the second molecule is labeled with a second fluorescent dye and the second molecule can be detected by the emission fluorescence intensity of the molecule, In a still further embodiment, the first molecule can be detected using an antibody (monoclonal or polyclonal) to the fluorescent molecule in an ELISA assay.
The first fluorescent dye can be selected from, but not limited to, xanthene dye, CAL FLOUR®, ALEXA FLUOR®, OREGON GREEN®, carbocyanine, fluorescein, fluorescein isothiocyanate (FITC), earhoxy fmoreseeein, cyanine, rhodamine, tetrameihylrhodamine (Tamra), tetramethyl rhodamine isothiocyanate (TRITC), X rhodarrdne isothiocyanate (XRITC). TEXAS RED®, and indocyanine green (ICG),
Measurement of the concentration of the second molecule in the vascular system can be performed in vitro or in vivo, In the in vitro method, a sample of blood is drawn from the animal after the second molecule has reached a steady state equilibrium concentration in the vascular system of the animal. A plasma or serum supernatant is prepared from die blood sample by a method such as, but not limited to, ceutrifugation or filtration. The concentration of the second molecule is measured in the plasma or semm supernatant. In another embodiment, an ELISA assay can also be used to determine the level of the fluorescent molecule in the plasma or serum. In the in vivo method, the second molecule is measured directly in vivo within the vascular system of the animal without having to remove a blood sample from the animal. A preferred method for in vivo measurement of the second molecule is to use a second molecule labeled with a second fluorescent dye,
Another aspect of the invention is directed to a method for determining the interstitial fluid volume (IFV) in an animal comprising: (a) determining the extracellular fluid volume (ECFV) of the animal; (b) determining the total vascular plasma volume (TVPV) of the animal; and (c) calculating the IFV of the animal using the equation: 1FV=ECFV-TVPV. An apparatus for determining the ECVF and TVPV using these methods may comprise; (a) means for providing the injectate to the vascular system of the animal; (b) means for measuring C\ and C¾ in vivo in the vascular system of the animal; (c) means for calculating ECFV and TVPV; and (d) means for displaying the calculated values of ECFV and TVPV. Optionally, the apparatus may further comprise means for calculating iFV and displaying the calculated value of iFV, The apparatus may be a stand alone unit or incorporated into a hemodialysis device.
The method may further comprise an additional step of calculating the interstitial fluid volume (IFV) using the equation: IFV=ECFV-TVPV.
Other features and advantages of the invention will be apparent from the following specification taken in conjunction with the following drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG, 1 shows a decay curve (o) of the fluorescence from the larger fluorescent marker 150-kDa FiTC-dextran which was administered to a bilaterally anephric rat as described in Example 1, Also shown is the smoothed fluorescence curve (— ) of the fluorescence from the 150-kDa FiTC-dextran as well as a decay curve of the ratio of the fluorescence from the 3-kDa Texas ed-dextran to that of the 150-kDa FFfC dextran (— .cndot.---).
DETAILED DESCRIPTION
While this invention is susceptible of embodiments in many different forms, there is shown in the drawings and will herein be described in detail preferred embodiments of the invention with the understanding that the present disclosure is to be considered as an exemplification of the principles of the invention and is not intended to limit the broad aspect of the invention to the embodiments illustrated,
The present invention is related generally to measurement of body fluid volumes in an animal subject. The body fluid volumes of interes include extracellular fluid volume (ECFV), total vascular plasma volume (TVPV) and i terstitial fluid volume (WV). The methods are especially beneficial for subjects suffering from renal failure and particularly those undergoing renal dialysis. The animal subject may be a mammalian subject, and the mammalian subject may be a human, The renal failure may be acute or chronic. Acute renal failure may be due to acute renal injury, and chronic renal failure may be due to late stage renal disease (ESRD). Renal dialysis can be hemodialysis or peritoneal dialysis if the abdominal cavity is dry. The renal failure may also be temporary or permanent.
In brief, ECFV can be measured by administering a first molecule which is non- metabolized and permeable to vessel wails of the vascular system wherein the first molecule is distributed within the total vascular spaces as well as the interstitial spaces. TVPV can be measured by administering a second molecule which is non-metabolized and impermeable to vessel walls of the vascular system wherein the second molecule is distributed within only the vascular spaces. IFV can then be calculated using the equation 1FV=ECFV-TVPV.
What is meant by total vascular plasma volume (TVPV) as used in the present application is the amount of plasma volume contained within the entire vascular space including arterial, venous and capillary spaces, The TVPV does not include the volume contributed by the blood cells, such as the red blood cells, TVPV may also be referred to as the Plasma Volume (PV). What is meant by interstitial fluid volume (WV) as used in the present application is the amount of volume extra vascular and surrounding cells as well as collections of fluid such as ascites or pleural fluid, IFV is a good indicator for capillary leakage, Expanded IFV is indicative that fluid is leaking from the vascular system and accumulating into the interstitial space which results in edema. The extracellular fluid volume (ECFV) as used in the present application is the sum of the TVPV and IFV. The relationship between these volumes can, therefore, be represented by the following equation:
ECFV=TVFV+IFV (1) Total blood volume (TBV) can be estimated from the TVPV by adding TVPV and the volume contributed by the blood cells, which can be determined from the Hematocrit (Hc ) or from the Packed Cell Volume (PCV),
One aspect of the present invention is directed to methods for measuring extraceullar fluid volume (ECFV) in an animal with renal failure. The method comprises: (a) administering a sufficient amount (Ai) of a first molecule to the vascular system of the animal wherein the first molecule is non-metabolized and permeable to vessel walls of the vascular system; (b) allowing the first molecule to reach a first equilibrium steady state concentration (Cj) in the vascular system of the animal; (c) measuring the Ci in the vascular system of the animal; and (d) calculating the ECFV using the. equation:
Figure imgf000009_0001
Another aspect of the present invention is directed to methods for determining total vascular plasma volume (TVPV) in an animal comprising: (a) administering a sufficient amount (A2) of a second molecule to the vascular system of the animal, wherein the second molecule is non-metabolized and impermeable to vessel wails of the vascular system; (b) allowing the second molecule to reach a second equilibrium steady state concentration in th plasma within the vascular system of the animal; (c) measuring the second equilibrium steady state concentration (€ ) of the second molecule; and calculating the TVPV using the equation; TVPV~A2/C2,
Once the ECFV and the TVPV are determined, interstitial fluid volume (IFV) can be calculated using the equation:
IFV=ECFV-TVPV (2)
What is meant by a sufficient amount of the first molecule or the second molecule is that the molecule is above the detection limit using an appropriate analytical technique after the molecule has reached equilibrium following distribution. The appropriate analytical method depends on the properties and characteristics of the molecule.
Examples of commonly used analytical methods include but are not limited to absorption spectroscopy, fluorescence, adsorption, ELISA assays, and the radioactive activity of the molecule. The time for the first molecule or the second molecule to reach its respectively steady state equilibrium concentration depends on the molecule and the animal species. Such time for reaching equilibrium can easily be determined by dosing the animal with the molecule and monitoring the molecule in the vascular system of the animal over time. Initially, the concentration of the molecule rises in the vascular system, which represents a mixing phase of the molecule in the vascular system. Eventually, the concentration of the molecule reaches an equilibrium steady state in the vascular system when the concentration plateaus. The beginning of the plateau of the concentration of the molecule marks the end of the mixing phase, An example of such a method is described in
Example 1 below. This equilibrium time is relatively constant for a specific molecule and a specific animal species so that once such time is determined for the molecule and the animal species, the value can be used for the same molecule and the same animal species without having to determine the value again. In human beings, the equilibrium time, is about 10 to 15 minutes for most molecules. However, in certain disease states, such as congestive heart failure, it may take longer time to reach equilibrium.
The first molecule or the second molecule may be administered by a suitable method such as intravenous injection of an injectate containing the first molecule and/or the second molecule, The intravenous injection can be bolus or continuous infusion over a period of time.
What is meant by "non-metabolized" is that the molecule is not significantly metabolized by the animal during the time in which the measurements are performed , What is meant by "permeable to vessel walls" refers to that the molecule can cross the vessel walls. This movement of the molecule can be a passive method without requiring energy, e.g. diffusion, or an active method requiring energy, e.g. active transport.
Similarly, "impermeable to vessel walls" refers to that the molecule cannot cross the vessel walls either through a passive process or an active process.
An EL1SA assay uses a solid-phase enzyme immunoassay (FJA) to detect the presence of the fluorescent dye attached to the dextran. In an ELISA assay, the fluorescent dye is affixed to a surface, and an antibody (monoclonal or polyclonal) is applied to the surface to bind with the dye. The antibody is linked to an enzyme, and in the final step, a substance containing the enzyme's substrate is added. The subsequent reaction produces a detectable signal, most commonly a color change in the substrate, ELISA assays are generally well known in the art.
In an embodiment, the first molecule has a molecular size of from about 1 kDa to about 20 kDa, In another embodiment, the second molecule has a molecule size of from about 70 kDa to about 500 kDa. In yet another embodiment, the first or the second molecule are dextrans. In a further embodiment, the first molecule or the second molecule is a fluorescent molecule, In vet a further embodiment, the first molecule is a dextran labeled with a first fluorescent dye having a first excitation wavelength and a first emission wavelength. In still a further embodiment, the second molecule is a dextran labeled with a second fluorescent dye having a second excitation wavelength and. a second emission wavelength, The first or second fluorescent dye can be selected from, but not limited to, xanthene dye, CAL FLOUR®, ALEXA FLUOR©, OREGON
GREEN®, carbocyanine, fluorescein, fluorescein isothiocyanate (FITC), carboxy fluoresecein, cyanine, rhodamine, tetranietnylrhodamine (Tamra), tetramethy! rhodamine isothiocyanate (TR1TC), X rhodamine isothiocyanate (XRITC), TEXAS RED® and indocyanine green (ICG).
Measurement of the concentration of the first molecule or the second molecule in the vascular system can be performed in vitro or in vivo. In the in vitro method, a sample of blood is drawn from the animal after the first molecule or the second molecule has reached a steady state equilibrium concentration in the vascular system of the animal. A plasma or semm supernatant of the blood is prepared from the blood sample by a method which removes the blood cells from the blood, such as, but not limited to, centrifugation or filtration, These separation methods are well known to those skilled in the art and are routinely practiced in the laboratory. The supernatant represents th piasrna of the blood. The concentration of the first molecule or the second molecule can be measured in the supernatant by an appropriate detection method such as absorption spectroscopy, fluorescence, or by using an ELISA immunoassay as described in mor detail in the Examples.
In the in vivo method, the first or the second molecule is measured directly in vivo within the vascular system of the animal wi thout having to remove a blood sample from the animal. A preferred method for in vivo measurement of a molecule is to use a molecule labeled with a fluorescent dye. An example of an in vivo measurement of a fluorescent molecule in the vascular system of the animal has been disclosed in a pending U.S. Pat. No. 12/425,827 which is incorporated herein by referenc and made a part of the present application. The method is applicable to measuring one or more fluorescent molecules simultaneously in vivo.
A further aspect of the invention is directed to methods for simultaneously measuring extracellular fluid volume (ECFV) and total vascular volume (TVPV) in an animal with renal failure comprising: (a) providing an injeetate containing a known amount Ai of a first molecule and a known amount A2 of a second molecule, wherein the first molecule is non-metabolized and permeable to vessel walls of the vascular system of the animal and the second molecule is non-metabolized and impermeable to vessel walls of the vascular system of the animal; (b) administering the injeetate into the vascular system of the animal; (c) allowing the first molecule to reach a first equilibrium steady state concentration Cs and the second molecule to reach a second equilibrium steady state concentration C2; (d) measuring d and C2 in the vascular system of the animal; and (e) calculating ECFV using the equation
Figure imgf000012_0001
and TVPV using the equation
TVPv=A2/e2.
Measurement of the concentration of the first molecule and the second molecule in the vascular system can be performed in vitro or in vivo. In the in vitro method, a sample of blood is drawn from the animal after the first molecule and the second molecule have each reached a steady state equilibrium concentration in the vascular system of the animal, A plasma or serum supernatant is prepared from the blood sample by a method such as, hut not limited to, centrifug tion or filtration. The concentration of the first molecule and the second molecule is measured in the supernatant. In the in vivo method, the first molecule and the second molecule are measured directly in vivo within the vascular system of the animal without having to remove a blood sample from the animal. A preferred method for in vivo measurement of the first molecule and the second molecule is to use a first molecule labeled with a first fluorescent dye and a second molecule labeled with second fluorescent dye,
The method may further comprise an additional step of calculating the interstitial fluid volume (1FV) using the equation: IFV=ECFV-TVPV. An apparatus for determining the ECFV and TVPV using these methods may comprise: (a) means for providing the injectate to the vascular system of the animal; (b) means for measuring Ci and C2 in vivo in the vascular system of the animal; fe) means for calculating ECFV and TVPV; and (d) means for displaying the calculated values of ECFV and TVPV. Optionally, the apparatus may further comprise means for calculating IFV and displaying the calculated value of IFV. The apparatus may be a stand alone unit or incorporated into a hemodialysis device.
The methods and compositions of the invention can be typically used in a clinic or hospital where the treatment of renal disease and renal failure are indicated.
The invention is further illustrated by the examples provided below, which are directed to certain embodiments of the invention and are not intended to limit the full scope of the invention as set forth in the appended claims.
EXAMPLES
Example 1: Measurement of TVPV and ECFV in Bilaterally Anephric Rats
The example shown here was a test conducted on a bilaterally anephric rat, which was infused with a mixture of 3 kDa TEXAS RED®-dextran and 150 kDa FiTC-dextran. The dynamic plasma fluorescence intensity was obtained by in vivo two-photon liver imaging of vascular plasma. Only the vascular plasma containing regions in each image were included for calculation. The decay curve of the fluorescence intensity of the 150- kDa FiTC- dextran as well as the decay curve of the ratio of the fluorescence intensity of the TEXAS RED©-dextran to that of the FiTC-dextran after the infusion is shown in FIG. L Using the ratio rather than the 3 kDa TEXAS RED®~dextran or the 150 kDa FiTC-dextran signal directly helped reduce the signal fluctuation caused by focus movement during imaging since the same fluctuation showed up in both channels.
To test if the volumes determined by this method agree with expected values we injected a xnixture of 3 Da TEXAS REB©-dextran and 150kDa FiTC-dextran to two bilaterally anephric rats. Blood was drawn from the animals 15 minutes after the infusion. According to the FIG, 1, this should be more than enough time for the dextrans to become equilibrated between the vascular and the interstitial spaces. The blood plasma was then separated by centrifuge. Fluorescence was measured using a spectrophotometer. TVPV and ECFV from each rat were determined using equations 4 and 5, respectively, The measured volumes along with estimated plasma volumes by body weight are shown ira the following table.
TABLE 1 : Measured and Estimated Plasma Volumes in Anephric Rats
Figure imgf000014_0001
Estimated TVPV valises were obtained from a method described by Altman P, L. ("Blood and Other Body Fluids", Fed. of Am. Societies for Experimental Biology (1961 ), Washington, D.C.) and Yu W, et al. ("Rapid Determinations of Renal Filtration Function using an Optical Raiiometric Image Approach", Am, J. Physiology-Renal Physiology (2007) 292(6): Fl 873-80),
IFV can be calculated from the measured TVPV and ECFV using the equation IFV=ECFV-TVPV.
Example 2: Anticipated Minimally Invasive Method for Measuring Fluid Volumes in a
Patient with Renal Failure
A minimally invasive method for measuring TVPV, ECFV and TV in a patient with renal failure uses a small dextran (molecule size of about 1 kDa to about 20 kDa) labeled with a first fluorescent dye to distribute to the vascular and interstitial spaces and a large dextran (molecule size of about 70 kDa to about 500 kDa) labeled with a second fluorescent dye to distribute only to the vascular space of the animal. The molecules can be simultaneously detected in vivo using a dual channel fluorescence detection device and a proprietary fiber optic catheter. The fluorescence device and the fiber optic catheter have both been disclosed in a pending U.S. Patent Application Ser. No, 12/425,827, the disclosure of which is hereby incorporated by reference as if fully set forth herein and, more specifically, for this specific subject matter disclosed at Paragraphs [0077] to
[0093], and FIGS. 1 and 91-14 for the detector, and Paragraphs [0108] to [0112] and FIGS, 1, 16, and 17 for the fiber optic catheter,
The method comprises: (1 ) inserting the proprietary fiber optic catheter into a peripheral vein in the patient's upper extremity; (2) connecting the fiber optic catheter to the fluorescence device; (3) attaching a syringe containing 5 to 10 ml of an injectate containing the small and large fluorescent dextrans to the catheter; (4) injecting 1 ml of the injectate into the calibration chamber of the catheter, and backfilling with patient's blood; (5) calibrating the fluorescence detection device; (6) advancing the fiber optic line through the catheter and into the catheter; (7) allowing enough time (approximately 10 to 15 minutes) for the molecules to equilibrate in the patient; (S) detecting the fluorescence intensities of the small and large dextrans with the fluorescence device; (9) calculating the fluid volumes using a pre-programmed algorithm; and (10) displaying the values of the fluid volumes on a screen.
Some of the key advantages of this method are that it is fast (only takes about 15 minutes), accurate and inexpensive, More importantly, the fluid volumes can be determined using data from a single time point,
Example 3: Measurement of TVFV and ECFV in Bilaterally Anephric Rats
Determination of plasma volume is accomplished using a 150 kDa dextran conjugated to a 2-Sulf ydroRhodamine (2SHR) fluorescent dye, A bolus injection or alternatively a rapid infusion of the molecule is given to the subject. A blood sample is taken approximately 10 to 15 minutes after the molecule enters the subjects blood stream. The sample is analyzed to determine the concentration of the molecule in the blood plasma. Thi s analysis can be advantageously accomplished using an ELISA colorimetric immunoassay containing monoclonal antibodies directed against 2SHR, Calculation of the plasma volume (PV) is determined as follows: PV ~ Dose/PC, where die Dose is the concentration per ml in the dose solution, and PC is the concentration of the fluorescent molecule contained in the plasma per ml,
The ELIS A coiorimeirie assay is incorporated into a module that allows determination of the plasma volume at the patient's bedside. A pair of ELiSA assays on one module allows for both PV and GFR (glomerular filtration rate) determination, the difference being that for the GFR detennination, more than one blood sample is drawn and measured.
While the specific embodiments have been illustrated and described, numerous modifications come to mind without significantly departing from the spirit of the invention, and the scope of protection is only limited by the scope of the accompanying claims.

Claims

What is claimed is: CLAIMS
1 , A method for measuring extracellular fluid volume (ECVF) in an animal with renal failure comprising: (a) administering a sufficient amount (At) of a first moiecuie to the vascular system of the animal wherein the first molecule is non-metabolized and peniieable to vessel walls of the vascular system; (b) allowing the first moleciile to reach a first equilibrium steady state concentration (Ci) in the vascular system of the animal; (c) measuring the Cj in the vascular system of the animal; and (d) calculating the ECFV using the equation: ECFV==A|/C] .
2. The method of claim 1 wherein the administration of the first moiecuie is by intravenous injection of a first injectate containing the first molecule,
3. The method of claim 2 wherein the injection is a bolus injection or an infusion,
4, The method of claim 1 wherein the administration is by inhalation,
5, The method of claim 1 wherein the first molecule has a molecular size of from about 1 kDa to about 20 kDa.
6. The method of claim 1 wherein the first molecule is a dextran,
7, The method of claim 1 wherein the first molecule is labeled with a first fluorescent dye having a first excitation wavelength and a first emission wavelength.
8. The method of claim 7 wherein the first fluorescent dye is selected from the group consisting of xanthene dye, CAL FLOUR®, ALEXA FLUOR®, OREGON GREEN®, carbocyanine, fluorescein, fluorescein isothiocyanate (FITC), carboxy fluoresecein, c anine, rhodamine, tetramethylrhodamine (Tamra). tetramethyl rhodamine
isothiocyanate (TR1TC), X rhodamine isothiocyanate (XRITC), TEXAS RED© and indpcyanine green (ICG).
9. The method of claim I wherein the animal is a mammal.
10. The method of claim 1 wherein the mammal is a human,
11. The method of cla m 1 wherein the renal failure s acute or chronic.
1.2, The method of claim 1 wherein the renal failure is temporary or permanent.
13. The method of claim 1 wherein the step (c) of measuring Ci includes: (a) withdrawing a sample of blood from the vascular system of the animal; (b) obtaining a plasma supernatant from the blood sample; and (c) measuring C] in the supernatant of the sample,
14. The method of claim 13 wherein Q is detected and quantified in vitro by the fluorescence intensity of the molecule.
15. The method of claim. 13 wherein Ci is detected and quantified in vitro using an ELISA assay containing antibodies to the fluorescent dye.
16. The method of claim. 1 wherein the step (c) is performed in vivo,
17. A method for measuring total vascular plasma volume (TVPV) of an animal comprising: (a) administering a sufficient amount (A2) of a second molecule to the vascular system of the animal, wherein the second molecule is non-metabolized and impermeable to vessel walls of the vascular system; (b) allowing the second molecule to reach a second equilibrium steady state concentration in the plasma within the vascular system of the animal; (c) meavSuring the second equilibrium steady state concentration (C2) of the second molecule; and (d) calculating the TVPV using the. equation:
TVPV=A2/C2.
18. The method of claim 17 wherein the administration of the second molecule is by intravenous injection of a second injectate containing the second molecule,
19. The method of claim 18 wherein the injection is a bolus injection or an infusion.
20. The method of claim 18 wherein the administration is by inhalation.
21. The method of claim 17 wherein the first molecule has a molecular size of from about 70 kDa to about 500 kDa.
22. The method of claim 17 wherein the first molecule is a dextran,
23. The method of claim 17 wherein the second molecule is labeled with a second fluorescent dye having a second excitation wavelength and a second emission wavelength.
24. The method of claim 17 wherein the second fluorescent dye is selected from the group consisting of xanthene dye, CAL FLOUR®, ALEXA FLUOR®, OREGON GREEN®, carbocyanine, fluorescein, fluorescein isothiocyanate (FITC), carboxy fluoresecein, cyaniiie, rhodamine, tetramethylfhodamine (Tanira), tetramethyl rhodamine isothiocyanate (TRITC), X rhodamine isothiocyanate (XRITC), TEXAS RED® and indoeyariifie green (ICG),
25. The method of claim 17 wherein the step (c) of measuring C2. includes; (a) withdrawing a sample of blood from the vascular system of the animal; (b) obtaining a plasma supernatant from the blood sample; and (c) measuring C2 in the supernatant of the sample.
26. The method of claim 25 wherein C2 is detected and quantified in vitro by the fluorescence intensity of the molecule.
27. The method of cl im 25 wherein C2 is detected and quantified in vitro using an ELISA assay containing antibodies to the fluorescent dye.
28. The method of cl im 25 wherein the step (e) is performed in vivo.
29. A method for determining the interstitial fluid volume (iFV) in an animal comprising: (a) determining the extracellular fluid volume (ECFV) of the animal; (b) determining the total vascular plasma volume (TVPV) of the animal; and (c) calculating the IFV of the animal using the equation: IFV-ECFV-TVPV.
PCT/US2015/020140 2009-04-30 2015-03-12 Improved measurement of body fluid volumes WO2015138702A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US15/125,412 US20170173188A1 (en) 2009-04-30 2015-03-12 Measurement of body fluid volumes
EP15761804.2A EP3117211A4 (en) 2014-03-13 2015-03-12 Improved measurement of body fluid volumes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/208,828 US20140193343A1 (en) 2009-04-30 2014-03-13 Measurement of body fluid volumes
US14/208,828 2014-03-13

Publications (1)

Publication Number Publication Date
WO2015138702A1 true WO2015138702A1 (en) 2015-09-17

Family

ID=54072394

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/020140 WO2015138702A1 (en) 2009-04-30 2015-03-12 Improved measurement of body fluid volumes

Country Status (2)

Country Link
EP (1) EP3117211A4 (en)
WO (1) WO2015138702A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164107A (en) * 2018-10-05 2021-07-23 药物影像股份有限公司以法斯特生物医疗公司名义经营 Method and apparatus for determining gap volume

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010127136A2 (en) * 2009-04-30 2010-11-04 Pharmacophotonics, Inc. Measurement of body fluid volumes
WO2013121368A2 (en) * 2012-02-15 2013-08-22 Biocon Limited A process for detection and optional quantification of an analyte

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007097961A1 (en) * 2006-02-16 2007-08-30 Massachusetts Eye & Ear Infirmary Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
US9462973B2 (en) * 2012-07-27 2016-10-11 Biocrine Ab Methods for monitoring physiological status of a body organ

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010127136A2 (en) * 2009-04-30 2010-11-04 Pharmacophotonics, Inc. Measurement of body fluid volumes
WO2013121368A2 (en) * 2012-02-15 2013-08-22 Biocon Limited A process for detection and optional quantification of an analyte

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3117211A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113164107A (en) * 2018-10-05 2021-07-23 药物影像股份有限公司以法斯特生物医疗公司名义经营 Method and apparatus for determining gap volume
EP3860460A4 (en) * 2018-10-05 2022-07-20 Pharmacophotonics, Inc. D/B/A Fast Biomedical Method and apparatus for determining interstitial volume

Also Published As

Publication number Publication date
EP3117211A4 (en) 2017-10-11
EP3117211A1 (en) 2017-01-18

Similar Documents

Publication Publication Date Title
AU2016203108A1 (en) Measurement of Body Fluid Volumes
US20220354403A1 (en) Renal function analysis method and apparatus
Molitoris et al. Quantifying glomerular filtration rates in acute kidney injury: a requirement for translational success
Wang et al. Rapid diagnosis and quantification of acute kidney injury using fluorescent ratio-metric determination of glomerular filtration rate in the rat
Wang et al. A portable fiberoptic ratiometric fluorescence analyzer provides rapid point-of-care determination of glomerular filtration rate in large animals
US8591865B2 (en) Renal function analysis method and apparatus
Yu et al. Rapid determination of renal filtration function using an optical ratiometric imaging approach
Jacob et al. Technical and physiological background of plasma volume measurement with indocyanine green: a clarification of misunderstandings
Proulx et al. Non-invasive dynamic near-infrared imaging and quantification of vascular leakage in vivo
Molitoris Rethinking CKD evaluation: should we be quantifying basal or stimulated GFR to maximize precision and sensitivity?
JP2021508526A (en) Devices and methods for measuring blood volume
US20210379206A1 (en) Compositions and methods for measuring and expanding blood volume
Morelle et al. Quantification of osmotic water transport in vivo using fluorescent albumin
US20170173188A1 (en) Measurement of body fluid volumes
WO2015138702A1 (en) Improved measurement of body fluid volumes
US20140301952A1 (en) Measurement of body fluid volumes
CN105527449A (en) Apolipoprotein A1 immunoturbidimetry detection kit
A Molitoris et al. Quantifying glomerular filtration rates: kidney function analysis method and apparatus
Ando et al. Predictors of worsening renal function after computed tomography coronary angiography: assessed by cystatin C
Assaly et al. Use of multiple fluorophores for evaluating microvascular permeability in control rats and rats with sepsis
WO2011130304A2 (en) Materials and methods for reliable measurement of blood volume
JP2022504413A (en) Methods and devices for determining gap volume

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15761804

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 15125412

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015761804

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015761804

Country of ref document: EP